Trevi Therapeutics, Inc. · NASDAQ:TRVI

Trevi Therapeutics — Technical Presentation (November 2025)

13 slides from Trevi Therapeutics's technical presentation, Nov 13, 2025

1. Slide 1: Phase 2b Study of Nalbuphine ER for Chronic Cough in IPF

   A Randomized, Placebo-Controlled, Parallel-Group Phase 2b Study of Nalbuphine ER for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis Philip Molyneaux, MD, PhD Professor of Interstitial Lung Disease Imperial College London, London UK Professor of Pulmonary Medicine Royal Brompton Hospita

2. Slide 2: Financial Disclosures

   Financial Disclosures  Institutional grant funding from AstraZeneca, GSK, Asthma & Lung UK, and Action for Pulmonary Fibrosis  Consulting fees from Boehringer Ingelheim, AstraZeneca, Caluna, Continum, GlaxoSmithKline, Gossamer Bio, Puretech, Qureight, Redx, IQVIA, Roche, Vicore and Trevi Therapeut

3. Slide 3: Chronic Cough in Patients with IPF

   Chronic Cough in Patients with IPF  Chronic cough affects 85% of patients with IPF and is associated with disease progression, reduced quality of life, and poor health outcomes1-6  There are currently no approved treatments for chronic cough in patients with IPF in the US  Oral nalbuphine extende

4. Slide 4: CORAL Phase 2b Study Design

   CORAL Phase 2b Study Design Primary Efficacy Endpoint • Relative change from Baseline in 24- hour cough frequency versus placebo at Week 6 (using objective cough monitoring) Secondary Efficacy Endpoints • E-RS®:IPF Cough Subscale • CS-NRS • 24-hour cough frequency responder analysis (using objective

5. Slide 5: Patient Demographics/Baseline Characteristics

   Patient Demographics/Baseline Characteristics Total (N = 165)1 Age (years), mean (std) 70.1 (7.29) Gender Male, n (%) 118 (71.5%) Female, n (%) 47 (28.5%) Forced vital capacity, mean (SD), L 2.56 (0.87) DLCO, mean (SD), % predicted 51.9 (16.56) Cough Duration (years), Mean (std) 4.22 (6.60) Mean Dos

6. Slide 6: Primary Endpoint: Objective 24-Hour Cough Frequency

   Primary Endpoint: Objective 24-Hour Cough Frequency * p<0.01 ** p<0.001 *** p<0.0001 mITT population Primary efficacy analysis conducted on log-transformed cough frequency data ^One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat mITT population

7. Slide 7: Objective 24-Hour Cough Frequency by Study Week

   Objective 24-Hour Cough Frequency by Study Week Placebo (N=40) 27 mg BID (N = 42) 54 mg BID (N = 43) 108 mg BID (N= 40) * p<0.01 ** p<0.001 *** p<0.0001 mITT population, Primary efficacy analysis conducted on log-transformed cough frequency data ^One placebo patient with an extreme outlier value at

8. Slide 8: Patient-Reported Outcome Measures

   Patient-Reported Outcome Measures Patient reported outcomes show measurable impact on patients E-RS®:IPF Cough Subscale: Relative Change from Baseline at Week 6 Cough Severity Numerical Rating Scale (CS-NRS) at Week 6 Placebo (N=40) 27 mg BID (N = 42) 54 mg BID (N = 43) 108 mg BID (N= 40) mITT popul

9. Slide 9: Patient Reported Quality of Life: Leicester Cough Questionnaire (LCQ)

   Patient Reported Quality of Life: Leicester Cough Questionnaire (LCQ) Statistically significant improvement in LCQ Total Score at 54 mg BID and 108 mg BID dose groups Baseline: 11.33 mITT population QoL, Quality of life

10. Slide 10: Treatment Emergent Adverse Events Overview

    Treatment Emergent Adverse Events Overview • No deaths occurred in this trial • SAEs occurred in patients at a higher rate in the placebo dose group (10%) than the active dose group (1.6%) • Discontinuations due to TEAEs were similarly distributed across the placebo (5.0%) and active (5.6%) dose gro

11. Slide 11: Summary of Common TEAEs by Preferred Term

    Summary of Common (≥ 10% in Total Active Group) TEAEs by Preferred Term • Majority of the common TEAEs were mild (Grade 1) or moderate (Grade 2) and consistent with prior NAL ER studies and the class of drug • Nausea, vomiting, constipation, dizziness, headache, and dry mouth all reported as either

12. Slide 12: CORAL Trial Conclusions

    CORAL Trial Conclusions  First parallel-group study that demonstrated significant reduction in cough frequency in patients with IPF  NAL ER was observed to result in statistically significant dose-related reduction in cough frequency  Statistically-significant changes in secondary endpoints, supp

13. Slide 13: Thank You!

    2 CHEST Thank You!

Trevi Therapeutics — Technical Presentation (November 2025) on 6ix